Literature DB >> 12598144

Effect of ibuprofen on cardioprotective effect of aspirin.

T M MacDonald1, L Wei.   

Abstract

Treatment with ibuprofen might limit the cardioprotective effects of aspirin. We aimed to assess whether patients with known cardiovascular disease who take low-dose aspirin and ibuprofen have increased risk of cardiovascular mortality. We studied 7107 patients who were discharged after first admission for cardiovascular disease between April, 1989, and April, 1997, and who were prescribed low-dose aspirin (<325 mg/day) and survived for at least 1 month. Compared with those who used aspirin alone, patients taking aspirin plus ibuprofen had an increased risk of all-cause mortality (adjusted hazard ratio 1.93, 95% CI 1.30-2.87, p=0.0011) and cardiovascular mortality (1.73, 1.05-2.84, p=0.0305). Our finding lends support to the hypothesis that ibuprofen may interact with the cardioprotective effects of aspirin, at least in patients with established cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598144     DOI: 10.1016/s0140-6736(03)12509-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  78 in total

1.  Giving aspirin and ibuprofen after myocardial infarction.

Authors:  Stephen E Kimmel; Brian L Strom
Journal:  BMJ       Date:  2003-12-06

2.  Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study.

Authors:  Jeptha P Curtis; Yongfei Wang; Edward L Portnay; Frederick A Masoudi; Edward P Havranek; Harlan M Krumholz
Journal:  BMJ       Date:  2003-12-06

Review 3.  Cardiology.

Authors:  Tom Fahey; Knut Schroeder
Journal:  Br J Gen Pract       Date:  2004-09       Impact factor: 5.386

4.  Do NSAIDs inhibit the cardioprotective effects of ASA?

Authors:  Sheldon M Singh; David A Alter
Journal:  CMAJ       Date:  2004-03-30       Impact factor: 8.262

5.  Aspirin resistance.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  BMJ       Date:  2004-02-28

6.  [NSAIDS and cardiovascular risk].

Authors:  Rosa Madridejos Mora
Journal:  Aten Primaria       Date:  2011-12-22       Impact factor: 1.137

Review 7.  [Polypharmacy and pain treatment].

Authors:  Markus Gosch; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Bernhard Iglseder; Monika Lechleitner; Ronald Otto; Regina E Roller; Ulrike Sommeregger
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 8.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

9.  Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation.

Authors:  Jan Hartinger; Robert Novotny; Jana Bilkova; Tomas Kvasnicka; Petr Mitas; Martin Sima; Jaroslav Hlubocky; Jan Kvasnicka; Ondrej Slanar; Jaroslav Lindner
Journal:  Med Princ Pract       Date:  2018-05-13       Impact factor: 1.927

Review 10.  Celecoxib: a review of its use in the management of arthritis and acute pain.

Authors:  James E Frampton; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.